|Printable version||E-mail this to a friend|
How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
Disaster resilience - CoR mobilises to turn global commitments into local action28/03/2017 14:25:00
The European Committee of the Regions (CoR), EC and the United Nations Office for Disaster Risk Reduction (UNISDR) seek to accelerate the implementation and monitoring of the Sendai Framework at the European Forum for Disaster Risk Reduction in Istanbul, in order to reduce the impact of natural disasters.
ESMA discusses haircuts in EU securities financing transactions28/03/2017 13:25:00
The European Securities and Markets Authority (ESMA) issued a research piece on shadow banking published in its recent report on trends, risks and vulnerabilities (TRV).
EC gives a boost to youth mobility in Europe28/03/2017 12:25:00
The EC has presented an initiative under the Erasmus+ programme which further supports learning and mobility of young Europeans.
Mergers: EC clears merger between Dow and DuPont, subject to conditions28/03/2017 11:25:00
The EC has approved under the EU Merger Regulation the proposed merger between US-based chemical companies Dow and DuPont. The approval is conditional in particular on the divestiture of major parts of DuPont's global pesticide business, including its global R&D organisation.
MEPs vote to close loopholes for exploiting EU and third country tax differences28/03/2017 10:25:00
Economic and Monetary Affairs Committee MEPs have voted to close loopholes which allow some of the world’s largest corporations to avoid paying tax on profits by exploiting differences in the tax systems of EU and third countries.